Subtype
High Grade Astrocytic Tumor
CI-CAN-00005503Explore in graph →
495 active trials2 approved drugs51 evidence items
- NCIt
- C102897
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005503Explore in graph →
Clinical trials
1,778 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (282)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04726397 | UNIty-Based MR-Linac Guided AdapTive RadiothErapy for High GraDe Glioma: a Phase 2 Trial(UNITED) | completed | N/A | 108 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT03232424 | NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma | completed | Phase 1 | 12 | Hackensack Meridian HealthOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05062772 | Brain Tumor Intraoperative Ultrasound Database(BraTioUS-DB) | completed | — | 150 | Hospital del Rio HortegaOTHER | 5 | Nov 15, 2024 | clinicaltrials |
| NCT03865355 | Blood and Cerebrospinal Fluid Metabolomic Profile in Glioma Patients | completed | — | 50 | Novosibirsk State UniversityOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT03732352 | 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma | completed | Phase 2 | 12 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04845919 | Sonodynamic Therapy With ExAblate System in Glioblastoma Patients(Sonic ALA) | completed | Phase 2 | 5 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT02101905 | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Nov 6, 2024 | clinicaltrials |
| NCT03922984 | Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Glioblastoma | completed | N/A | 43 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT04304300 | Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes(RIGEL) | completed | — | 80 | Erasmus Medical CenterOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03926507 | F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery | completed | N/A | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT01149850 | Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT01811992 | Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma | completed | Phase 1 | 19 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03234595 | A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma | completed | Phase 1 / Phase 2 | 22 | Everfront Biotech Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03278249 | Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma | completed | N/A | 12 | University of CincinnatiOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03661723 | Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03879512 | Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG | completed | Phase 1 / Phase 2 | 24 | Wuerzburg University HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06600399 | Correlation Between Prostate-specific Membrane Antigen Positron Emission Tomography and Arterial Spin Labeling Perfusion Imaging in Glioblastoma(PSMA，ASL，PET) | completed | — | 26 | Lanzhou University Second HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03995706 | Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0 | completed | Early Phase 1 | 26 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT01204684 | Dendritic Cell Vaccine for Patients With Brain Tumors | completed | Phase 2 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT04013672 | Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence | completed | Phase 2 | 41 | David PeereboomOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT01923922 | CT Perfusion in the Prognostication of Cerebral High Grade Glioma | completed | N/A | 48 | Nova Scotia Health AuthorityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06562621 | Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 38 | Beijing Neurosurgical InstituteOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT04492163 | Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM | completed | Phase 2 | 25 | NovoCure GmbHINDUSTRY | 1 | Aug 16, 2024 | clinicaltrials |
| NCT05977738 | Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin(ReDiReCCT-Pita) | completed | Early Phase 1 | 12 | C.DirvenOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06538428 | Methylation Patterns of the NUPR1, MGMT, NDRG2, and GLI1 Genes and Their Impact on Therapeutic Outcome of GBM Patients | completed | — | 78 | Ain Shams UniversityOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06038604 | Glioblastoma Psychosocial Support Program | completed | N/A | 11 | Duke UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03493932 | Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade | completed | Phase 1 | 21 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Jul 24, 2024 | clinicaltrials |
| NCT02441322 | Evaluating Therapeutic Response to Novo-TTF | completed | N/A | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT01817751 | Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma | completed | Phase 2 | 47 | Virginia Commonwealth UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06490497 | Expectations and Needs of a Glioblastoma Caregiver(GLOIOS) | completed | — | 9 | Hopital Nord Franche-ComteOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06346821 | Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World Data | completed | — | 181 | Sichuan UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Prelude TherapeuticsINDUSTRY | 2 | Jul 1, 2024 | clinicaltrials |
| NCT04937413 | The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation | completed | Early Phase 1 | 32 | Duke UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03434262 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | completed | Phase 1 | 68 | St. Jude Children's Research HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT02014844 | Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma | completed | Phase 2 | 28 | ImmunityBio, Inc.INDUSTRY | 1 | May 29, 2024 | clinicaltrials |
| NCT05402241 | IRD at Admission Predicts Survival of GBM Patients - a Prospective Pilot Study(IRD-GBM) | completed | — | 52 | University of ManitobaOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT02067156 | Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma | completed | Phase 2 | 26 | GenSpera, Inc.INDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT04604158 | Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients | completed | N/A | 38 | Gillian GreshamOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT01591577 | Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT03139916 | Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma | completed | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT04143425 | Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma | completed | — | 15 | Ho Sung KimOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT03776071 | A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 | completed | Phase 3 | 260 | Denovo Biopharma LLCINDUSTRY | 3 | Apr 22, 2024 | clinicaltrials |
| NCT02654964 | Cancer Stem Cell High-Throughput Drug Screening Study | completed | Phase 1 | 9 | Swedish Medical CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03043391 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | completed | Phase 1 | 8 | Istari Oncology, Inc.INDUSTRY | 1 | Apr 8, 2024 | clinicaltrials |
| NCT00589875 | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma(BrTK02) | completed | Phase 2 | 52 | Candel Therapeutics, Inc.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT03454295 | Easing Psychosocial Burden for Informal Caregivers | completed | Early Phase 1 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT03466450 | Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma(GEINOGLAS) | completed | Phase 1 / Phase 2 | 75 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT02052648 | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | completed | Phase 1 / Phase 2 | 160 | NewLink Genetics CorporationINDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT03770468 | Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma | completed | — | 599 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Mar 8, 2024 | clinicaltrials |
| NCT03712293 | ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy | completed | N/A | 9 | InSightecINDUSTRY | 1 | Mar 5, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 29, 2024source: clinicaltrials